Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002382 · ClinicalTrials.gov registry record · Phase 3
A Study of Saquinavir Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Patients
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 4,000
- Enrollment target
NCT00002382: Completed Phase 3 study, sponsored by Hoffmann-La Roche.
NCT00002382 is a Phase 3 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 4,000 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (418% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002382, a Phase 3 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 4,000 participants
- Enrollment target
Study Summary
To offer an investigational agent (saquinavir) to people with HIV/AIDS who are in need of additional treatment options and are not eligible to enroll in ongoing clinical trials. Patients who no longer benefit from existing antiretroviral therapy and who are not currently enrolled in ongoing saquinavir trials are eligible for this compassionate treatment program.
Interventions
- DRUG Saquinavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,000 participants |
| Phase | Phase 3 |
What the finished NCT00002382 record still lists
NCT00002382 is an interventional study that assigns participants to a tested intervention. Its 4,000 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (418% higher).
The record links to 0 conditions, and to 1 intervention - of which Saquinavir is the first listed.
NCT00002382 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002382 about?
NCT00002382 is a clinical study titled "A Study of Saquinavir Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Patients". To offer an investigational agent (saquinavir) to people with HIV/AIDS who are in need of additional treatment options and are not eligible to enroll in ongoing clinical trials. Patients who no longer benefit from existing antiretroviral therapy and who are not currently enrolled in ongoing saquina...
What is the current status of trial NCT00002382?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 4,000 participants.
What interventions are being tested in trial NCT00002382?
The interventions under investigation include: Saquinavir (DRUG).
Who is sponsoring clinical trial NCT00002382?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00002382's enrollment target sits among peer trials
4,000 61st of 2000 higher than 1,938 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00227253 · 4,000 participants
Chromosome 18 Clinical Research Center
- NCT00811148 · 4,000 participants
Florida Center for Brain Tumor Research
- NCT00897117 · 4,000 participants
Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer
- NCT00899301 · 4,000 participants
Collecting and Storing Tissue Samples From Women With or Without Breast Cancer